Hypha Labs (FUNI) 10-Q 15 Aug 22 2022 Q3 Quarterly report Financial data

Cover

Cover - shares	9 Months Ended
	Jun. 30, 2022	Aug. 15, 2022
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Quarterly Report	true
Document Transition Report	false
Document Period End Date	Jun. 30, 2022
Document Fiscal Period Focus	Q3
Document Fiscal Year Focus	2022
Current Fiscal Year End Date	--09-30
Entity File Number	000-54239
Entity Registrant Name	Digipath, Inc.
Entity Central Index Key	0001502966
Entity Tax Identification Number	27-3601979
Entity Incorporation, State or Country Code	NV
Entity Address, Address Line One	6450 Cameron St
Entity Address, Address Line Two	Suite 113
Entity Address, City or Town	Las Vegas
Entity Address, State or Province	NV
Entity Address, Postal Zip Code	89118
City Area Code	(702)
Local Phone Number	527-2060
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	true
Elected Not To Use the Extended Transition Period	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		75,146,820

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($)	Jun. 30, 2022	Sep. 30, 2021
Current assets:
Cash	$ 225,233	$ 295,932
Accounts receivable, net	245,095	214,900
Note receivable	551,969	230,929
Other current assets	64,425	60,353
Deposits	25,141	24,751
Total current assets	1,111,863	826,865
Right-of-use asset	341,734	413,884
Fixed assets, net	481,539	647,252
Total non-current assets	823,273	1,061,136
Total Assets	1,935,136	1,888,001
Current liabilities:
Accounts payable	487,078	370,977
Accrued expenses	438,664	220,002
Current portion of operating lease liabilities	100,685	93,601
Current portion of finance lease liabilities		20,379
Current maturities of convertible notes payable	1,728,702	1,050,000
Current maturities of notes payable	545,880	259,425
Total current liabilities	3,301,009	2,014,384
Non-current liabilities:
Operating lease liabilities	254,376	330,151
Notes payable	400,188	339,516
Convertible notes payable, net of discounts of $-0- and $8,322 at June 30, 2022 and September 30, 2021, respectively		257,282
Total non-current liabilities	654,564	926,949
Total Liabilities	3,955,573	2,941,333
Series B convertible preferred stock, $0.001 par value, 1,500,000 shares authorized; 333,600 and zero shares issued and outstanding as of June 30, 2022 and September 30, 2021 respectively	333,600
Stockholders’ Equity (Deficit):
Series A convertible preferred stock, $0.001 par value, 6,000,000 shares authorized; 1,047,942 and 1,325,942 shares issued and outstanding as of June 30, 2022 and September 30, 2021, respectively	1,048	1,326
Common stock, $0.001 par value, 250,000,000 shares authorized; 75,146,820 and 71,230,153 shares issued and outstanding at June 30, 2022 and September 30 2021, respectively	75,147	71,230
Additional paid-in capital	16,762,075	16,825,765
Accumulated deficit	(19,192,307)	(17,951,653)
Total Stockholders’ Deficit	(2,354,037)	(1,053,332)
Total Liabilities and Stockholders’ Deficit	$ 1,935,136	$ 1,888,001

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parenthetical) - USD ($)	Jun. 30, 2022	Sep. 30, 2021
Debt instrument, unamortized discount, noncurrent	$ 0	$ 8,322
Series A convertible preferred stock, par value	$ 0.001	$ 0.001
Series A convertible preferred stock, shares authorized	6,000,000	6,000,000
Series A convertible preferred stock, shares issued	1,047,942	1,325,942
Series A convertible preferred stock, shares outstanding	1,047,942	1,325,942
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	250,000,000	250,000,000
Common stock, shares issued	75,146,820	71,230,153
Common stock, shares outstanding	75,146,820	71,230,153
Series B Convertible Preferred Stock [Member]
Temporary equity, par value	$ 0.001	$ 0.001
Temporary equity, shares authorized	1,500,000	1,500,000
Temporary equity, shares issued	333,600	0
Temporary equity, shares outstanding	333,600	0

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended		9 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Income Statement [Abstract]
Revenues	$ 682,665	$ 764,015	$ 1,986,985	$ 1,897,560
Cost of sales	414,299	551,976	1,232,932	1,389,776
Gross profit	268,366	212,039	754,053	507,784
Operating expenses:
General and administrative	278,765	278,082	755,199	715,093
Professional fees	81,108	91,001	635,969	313,364
Change in allowance for doubtful accounts	66,712	(10,960)	64,589	(28,945)
Total operating expenses	426,585	358,123	1,455,757	999,512
Operating loss	(158,219)	(146,084)	(701,704)	(491,728)
Other income (expense):
Interest income	12,386		37,061
Interest expense	(72,230)	(31,130)	(217,341)	(105,840)
Credit loss	(358,670)		(358,670)
Other Income				47,918
Total other income (expense)	(418,514)	(31,130)	(538,950)	(57,922)
Net loss	$ (576,733)	$ (177,214)	$ (1,240,654)	$ (549,650)
Weighted average number of common shares outstanding – basic	75,146,820	68,479,201	73,845,233	64,081,692
Weighted average number of common shares outstanding – fully diluted	75,146,820	68,479,201	73,845,233	64,081,692
Net loss per share – basic and fully diluted	$ (0.01)	$ 0	$ (0.02)	$ (0.01)

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Stockholders' Deficit (Unaudited) - USD ($)	Series B Convertible Preferred Stock [Member]	Series A Convertible Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Total
Beginning balance at Sep. 30, 2020		$ 1,326	$ 58,271	$ 16,116,400	$ (17,265,150)	$ (1,089,153)
Beginning balance, shares at Sep. 30, 2020		1,325,942	58,270,567
Stock-based compensation			$ 1,228	42,832		44,060
Stock-based compensation, shares			1,228,155
Net Income (loss)					(390,637)	(390,637)
Common stock sold for cash			$ 900	19,350		20,250
Common stock sold for cash, shares			900,000
Common stock issued for debt conversion			$ 3,666	106,334		110,000
Common stock issued for debt conversion, shares			3,666,668
Ending balance at Dec. 31, 2020		$ 1,326	$ 64,065	16,284,916	(17,655,787)	(1,305,480)
Ending balance, shares at Dec. 31, 2020		1,325,942	64,065,390
Beginning balance at Sep. 30, 2020		$ 1,326	$ 58,271	16,116,400	(17,265,150)	(1,089,153)
Beginning balance, shares at Sep. 30, 2020		1,325,942	58,270,567
Net Income (loss)						(549,650)
Ending balance at Jun. 30, 2021		$ 1,326	$ 69,730	16,563,314	(17,814,800)	(1,180,430)
Ending balance, shares at Jun. 30, 2021		1,325,942	69,730,153
Beginning balance at Dec. 31, 2020		$ 1,326	$ 64,065	16,284,916	(17,655,787)	(1,305,480)
Beginning balance, shares at Dec. 31, 2020		1,325,942	64,065,390
Stock-based compensation			$ 250	29,647		29,897
Stock-based compensation, shares			250,000
Net Income (loss)					18,201	18,201
Common stock issued for debt conversion			$ 3,000	87,000		90,000
Common stock issued for debt conversion, shares			3,000,000
Stock-based compensation - related parties			$ 867	56,157		57,024
Stock-based compensationrelated party, shares			866,430
Ending balance at Mar. 31, 2021		$ 1,326	$ 68,182	16,457,720	(17,637,586)	(1,110,358)
Ending balance, shares at Mar. 31, 2021		1,325,942	68,181,820
Stock-based compensation			$ 1,465	78,035		79,500
Stock-based compensation, shares			1,465,000
Net Income (loss)					(177,214)	(177,214)
Stock-based compensation - related parties			$ 83	27,559		27,642
Stock-based compensationrelated party, shares			83,333
Ending balance at Jun. 30, 2021		$ 1,326	$ 69,730	16,563,314	(17,814,800)	(1,180,430)
Ending balance, shares at Jun. 30, 2021		1,325,942	69,730,153
Beginning balance at Sep. 30, 2021		$ 1,326	$ 71,230	16,825,765	(17,951,653)	(1,053,332)
Beginning balance, shares at Sep. 30, 2021		1,325,942	71,230,153
Purchase of Series B Preferred shares	$ 55,600
Purchase of Series B Preferred shares, shares	55,600
Conversion of Series A Preferred into Series B Preferred	$ 278,000	$ (278)		(277,722)		(278,000)
Conversion of Series A Preferred into Series B Preferred, shares	278,000	(278,000)
Stock-based compensation			$ 1,500	97,179		98,679
Stock-based compensation, shares			1,500,000
Net Income (loss)					(290,325)	(290,325)
Ending balance at Dec. 31, 2021	$ 333,600	$ 1,048	$ 72,730	16,645,222	(18,241,978)	(1,522,978)
Ending balance, shares at Dec. 31, 2021	333,600	1,047,942	72,730,153
Beginning balance at Sep. 30, 2021		$ 1,326	$ 71,230	16,825,765	(17,951,653)	(1,053,332)
Beginning balance, shares at Sep. 30, 2021		1,325,942	71,230,153
Purchase of Series B Preferred shares						$ 7,500
Purchase of Series B Preferred shares, shares						250,000
Net Income (loss)						$ (1,240,654)
Ending balance at Jun. 30, 2022	$ 333,600	$ 1,048	$ 75,147	16,762,075	(19,192,307)	(2,354,037)
Ending balance, shares at Jun. 30, 2022	333,600	1,047,942	75,146,820
Beginning balance at Dec. 31, 2021	$ 333,600	$ 1,048	$ 72,730	16,645,222	(18,241,978)	(1,522,978)
Beginning balance, shares at Dec. 31, 2021	333,600	1,047,942	72,730,153
Stock-based compensation			$ 2,167	101,297		103,464
Stock-based compensation, shares			2,166,667
Net Income (loss)					(373,596)	(373,596)
Common Shares issued for settlement of AP			$ 250	7,250		7,500
Common Shares issued for settlement of AP, shares			250,000
Ending balance at Mar. 31, 2022	$ 333,600	$ 1,048	$ 75,147	16,753,769	(18,615,574)	(1,785,610)
Ending balance, shares at Mar. 31, 2022	333,600	1,047,942	75,146,820
Stock-based compensation				8,306		8,306
Net Income (loss)					(576,733)	(576,733)
Ending balance at Jun. 30, 2022	$ 333,600	$ 1,048	$ 75,147	$ 16,762,075	$ (19,192,307)	$ (2,354,037)
Ending balance, shares at Jun. 30, 2022	333,600	1,047,942	75,146,820

Consolidated Statements of Cash

Consolidated Statements of Cash Flows (Unaudited) - USD ($)	9 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
Cash flows from operating activities
Net loss	$ (1,240,654)	$ (549,650)
Adjustments to reconcile net loss to net cash used in operating activities:
Change in allowance for doubtful accounts	64,589	(28,945)
Credit loss	358,670
Depreciation and amortization expense	169,959	233,663
Loss on disposal of fixed assets		2,227
Gain on early extinguishment of debt		(40,338)
Stock-based compensation	210,449	238,123
Amortization of debt discounts	58,654	8,322
Decrease (increase) in assets:
Accounts receivable	(94,784)	77,280
Other current assets	(41,133)	(15,277)
Deposits	(390)	(55,000)
Right-of-use assets	72,150	68,408
Increase (decrease) in liabilities:
Accounts payable	123,602	(47,454)
Accrued expenses	218,662	32,016
Lease liabilities	(68,691)	(62,471)
Net cash (used) in operating activities	(168,917)	(139,096)
Cash flows from investing activities
Purchase of fixed assets	(4,246)	(1,206)
Advance of note receivable	(817,649)
Proceeds from sale of collateralized assets	175,000
Net cash (used) in investing activities	(646,895)	(1,206)
Cash flows from financing activities
Principal payments on finance lease	(20,379)	(24,443)
Principal payments on note payable, equipment financing	(42,873)	(40,445)
Proceeds from short term advances		65,000
Proceeds from notes payable	390,000
Proceeds from convertible notes	402,765	110,000
Payments on convertible notes	(40,000)
Proceeds from sale of common stock		20,250
Proceeds from sale of preferred stock	55,600
Net cash provided by financing activities	745,113	130,362
Net increase (decrease) in cash	(70,699)	(9,940)
Cash - beginning	295,932	82,749
Cash - ending	225,233	72,809
Supplemental disclosures:
Interest paid	57,439	49,508
Income taxes paid
Non-cash investing and financing activities:
Common stock issued for debt conversion		200,000
Common stock issued for settlement of accounts payables	7,500
Conversion of Series A preferred into Series B preferred	$ 278,000

Organization, Basis of Presenta

Organization, Basis of Presentation and Significant Accounting Policies	9 Months Ended
	Jun. 30, 2022
Accounting Policies [Abstract]
Organization, Basis of Presentation and Significant Accounting Policies	Note 1 – Organization, Basis of Presentation and Significant Accounting Policies Organization Digipath, Inc. was incorporated in Nevada on October 5, 2010. Digipath, Inc. and its subsidiaries (“Digipath,” the “Company,” “we,” “our” or “us”) is a service-oriented independent testing laboratory, data analytics and media firm focused on the developing cannabis and hemp markets, and supports the cannabis industry’s best practices for reliable testing, cannabis education and training. Our mission is to provide pharmaceutical-grade analysis and testing to the cannabis industry, under ISO-17025:2017 guidelines, to ensure consumers and patients know exactly what is in the cannabis they ingest and to help maximize the quality of our clients’ products through research, development, and standardization. Digipath has been operating a cannabis-testing lab in Nevada since 2015 and hopes to open labs in other states that have legalized the sale of cannabis, beginning with California or Arizona. Basis of Presentation The accompanying consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“GAAP”). Intercompany accounts and transactions have been eliminated. The unaudited condensed consolidated financial statements of the Company and the accompanying notes included in this Quarterly Report on Form 10-Q are unaudited. In the opinion of management, all adjustments necessary for a fair presentation of the Condensed Consolidated Financial Statements have been included. Such adjustments are of a normal, recurring nature. The Condensed Consolidated Financial Statements, and the accompanying notes, are prepared in accordance with GAAP and do not contain certain information included in the Company’s Annual Report on Form 10-K for the fiscal year ended September 30, 2021. The interim Condensed Consolidated Financial Statements should be read in conjunction with that Annual Report on Form 10-K. Results for the interim periods presented are not necessarily indicative of the results that might be expected for the entire fiscal year. Principles of Consolidation The accompanying consolidated financial statements include the accounts of the following entities, all of which were under common control and ownership at June 30, 2022: Schedule of Entities Under Common Control and Ownership Jurisdiction of Name of Entity (1) Incorporation Relationship Digipath, Inc. (2) Nevada Parent Digipath Labs, Inc. Nevada Subsidiary Digipath Labs CA, Inc. (3) California Subsidiary Digipath Labs S.A.S. (4) Colombia Subsidiary VSSL Enterprises, Ltd. (5) Canada Subsidiary TNM News Corp. (6) Nevada Subsidiary (1) All entities are in the form of a corporation. (2) Holding company, which owns each of the wholly-owned subsidiaries. All subsidiaries shown above are wholly-owned by Digipath, Inc., the parent company. (3) Formed during the second fiscal quarter of 2021, but has not yet commenced significant operations. (4) Formed during the first fiscal quarter of 2019, but has not yet commenced significant operations. (5) Acquired on March 11, 2020. (6) Minimal activity, dissolved on July 28, 2021. The consolidated financial statements herein contain the operations of the wholly-owned subsidiaries listed above. All significant inter-company transactions have been eliminated in the preparation of these financial statements. The parent company and subsidiaries will be collectively referred to herein as the “Company”, “Digipath” or “DIGP”. The Company’s headquarters are located in Las Vegas, Nevada and substantially all of its customers are within the United States. These statements reflect all adjustments, consisting of normal recurring adjustments, which in the opinion of management are necessary for fair presentation of the information contained therein. Fair Value of Financial Instruments Under FASB ASC 820-10-05, the Financial Accounting Standards Board establishes a framework for measuring fair value in generally accepted accounting principles and expands disclosures about fair value measurements. This Statement reaffirms that fair value is the relevant measurement attribute. The adoption of this standard did not have a material effect on the Company’s financial statements as reflected herein. The carrying amounts of cash, accounts receivable, accounts payable and accrued expenses reported on the balance sheets are estimated by management to approximate fair value primarily due to the short-term nature of the instruments. Revenue Recognition The Company recognizes revenue in accordance with ASC 606 — Revenue from Contracts with Customers. Under ASC 606, the Company recognizes revenue from the commercial sales of products, licensing agreements and contracts to perform pilot studies by applying the following steps: (1) identify the contract with a customer; (2) identify the performance obligations in the contract; (3) determine the transaction price; (4) allocate the transaction price to each performance obligation in the contract; and (5) recognize revenue when each performance obligation is satisfied. Revenue is primarily generated through our subsidiary, Digipath Labs, Inc., which recognizes revenue from the analytical testing of cannabis products for licensed producers and cultivators within the state of Nevada on a determinable fixed fee per test, or panel of tests basis. Revenue from the performance of those services is recognized upon completion of the tests, at which time test results are delivered to the customer, provided collectability of the fee is reasonably assured. We typically require payment within thirty days of the delivery of results. Management estimates an allowance for doubtful accounts based on the aging of its receivables. Stock-Based Compensation The Company accounts for equity instruments issued to employees in accordance with the provisions of ASC 718 Stock Compensation (ASC 718) and Equity-Based Payments to Non-employees pursuant to ASC 2018-07 (ASC 2018-07). All transactions in which goods or services are the consideration received for the issuance of equity instruments are accounted for based on the fair value of the consideration received or the fair value of the equity instrument issued, whichever is more reliably measurable. The measurement date of the fair value of the equity instrument issued is the earlier of the date on which the counterparty’s performance is complete or the date at which a commitment for performance by the counterparty to earn the equity instruments is reached because of sufficiently large disincentives for nonperformance. Recently Issued Accounting Pronouncements There are no recently issued accounting pronouncements that the Company has yet to adopt that are expected to have a material effect on its financial position, results of operations, or cash flows.

Going Concern

Going Concern	9 Months Ended
	Jun. 30, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Going Concern	Note 2 – Going Concern As shown in the accompanying condensed consolidated financial statements, as of June 30, 2022, the Company had negative working capital of $ 2,189,146 19,192,307 225,233 The consolidated financial statements do not include any adjustments that might result from the outcome of any uncertainty as to the Company’s ability to continue as a going concern. These financial statements also do not include any adjustments relating to the recoverability and classification of recorded asset amounts, or amounts and classifications of liabilities that might be necessary should the Company be unable to continue as a going concern.

Fair Value of Financial Instrum

Fair Value of Financial Instruments	9 Months Ended
	Jun. 30, 2022
Investments, All Other Investments [Abstract]
Fair Value of Financial Instruments	Note 3 – Fair Value of Financial Instruments The Company discloses the fair value of certain assets and liabilities in accordance with ASC 820 – Fair Value Measurement The Company has certain financial instruments that must be measured under the new fair value standard. The Company’s financial assets and liabilities are measured using inputs from the three levels of the fair value hierarchy. The three levels are as follows: Level 1 - Inputs are unadjusted quoted prices in active markets for identical assets or liabilities that the Company has the ability to access at the measurement date. Level 2 - Inputs include quoted prices for similar assets and liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active, inputs other than quoted prices that are observable for the asset or liability (e.g., interest rates, yield curves, etc.), and inputs that are derived principally from or corroborated by observable market data by correlation or other means (market corroborated inputs). Level 3 - Unobservable inputs that reflect our assumptions about the assumptions that market participants would use in pricing the asset or liability. The following schedule summarizes the valuation of financial instruments at fair value on a recurring basis in the balance sheets as of June 30, 2022 and September 30, 2021, respectively: Summary of Financial Instruments at Fair Value on Recurring Basis Fair Value Measurements at June 30, 2022 Level 1 Level 2 Level 3 Assets Cash $ 225,233 $ - $ - Liabilities Lease liabilities - - 355,061 Notes payable - 946,068 - Convertible notes payable - - 1,728,701 Fair Value Measurements at September 30, 2021 Level 1 Level 2 Level 3 Assets Cash $ 295,932 $ - $ - Liabilities Lease liabilities - - 444,131 Notes payable - 598,941 - Convertible notes payable, net of discounts of $ 98,188 - - 1,307,282 The fair value of our intellectual properties are deemed to approximate book value, and are considered Level 3 inputs as defined by ASC Topic 820-10-35. There were no transfers of financial assets or liabilities between Level 1, Level 2 and Level 3 inputs for the nine months ended June 30, 2022 or the year ended September 30, 2021.

Note Receivable

Note Receivable	9 Months Ended
	Jun. 30, 2022
Receivables [Abstract]
Note Receivable	Note 4 – Note Receivable On various dates between December 28, 2018 and June 13, 2019, we loaned Northwest Analytical Labs, Inc. a total of $ 95,000 10 On various dates between August 23, 2021 and June 30, 2021, we loaned C3 Labs, Inc. (“C3 Labs”) a total of $ 1,047,649 8 August 23, 2022 37,061 37,991 The loans were made in connection with a potential acquisition of a controlling interest in C3 Labs pursuant to a letter of intent. On March 11, 2022, the Company notified the current owners of C3 Labs of its termination of the letter of intent. The Company is currently in possession of equipment of C3 Labs, which it is in the process of liquidating. The Company anticipates that the proceeds of such liquidation will be insufficient to repay the Company in full all amounts owed to it by C3 Labs, and as such has recorded an allowance of 358,670 175,000

Fixed Assets

Fixed Assets	9 Months Ended
	Jun. 30, 2022
Property, Plant and Equipment [Abstract]
Fixed Assets	Note 5 – Fixed Assets Fixed assets consist of the following at June 30, 2022 and September 30, 2021: Schedule of Fixed Assets June 30, 2022 September 30, 2021 Software $ 125,903 $ 125,903 Office equipment 71,601 71,601 Furniture and fixtures 29,879 29,879 Lab equipment 1,455,479 1,453,716 Leasehold improvements 496,600 494,117 Lab equipment held under capital leases 99,193 99,193 Fixed assets, gross 2,278,655 2,274,409 Less: accumulated depreciation (1,797,116 ) (1,627,157 ) Total $ 481,539 $ 647,252 Depreciation and amortization expense totaled $ 169,959 233,663

Leases

Leases	9 Months Ended
	Jun. 30, 2022
Leases
Leases	Note 6 – Leases The Company leases its operating and office facility under a non-cancelable real property lease agreement that expires on August 31, 2025 The components of lease expense were as follows: Schedule of Components of Lease Expense For the Nine For the Nine Months Ended Months Ended June 30, 2022 June 30, 2021 Operating lease cost $ 89,155 $ 6,477 Finance lease cost: Amortization of assets 72,187 68,408 Interest on lease liabilities 1,266 20,747 Total net lease cost $ 162,608 $ 95,632 Supplemental balance sheet information related to leases was as follows: Schedule of Supplemental Balance Sheet Information June 30, 2022 September 30, 2021 Operating leases: Operating lease assets $ 341,734 $ 413,884 Current portion of operating lease liabilities 100,685 $ 93,601 Noncurrent operating lease liabilities 254,376 330,151 Total operating lease liabilities $ 355,061 $ 423,752 Finance lease: Equipment, at cost $ 99,193 $ 99,193 Accumulated amortization (54,556 ) (39,677 ) Equipment, net $ 44,637 $ 59,516 Current portion of finance lease liabilities $ - $ 20,379 Noncurrent finance lease liabilities - - Total finance lease liabilities $ - $ 20,379 Weighted average remaining lease term: Operating leases 3.17 3.92 Finance leases 0.00 .55 Weighted average discount rate: Operating leases 5.75 % 5.75 % Finance lease 18.41 % 18.41 % Supplemental cash flow and other information related to leases was as follows: Schedule of Supplemental Cash Flow and Other Information For the Nine For the Nine Months Ended Months Ended June 30, 2022 June 30, 2021 Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows used for operating leases $ 45,490 $ 62,471 Financing cash flows used for finance leases $ 20,379 $ 24,443 Leased assets obtained in exchange for lease liabilities: Total operating lease liabilities $ - $ 528,616 Total finance lease liabilities $ - $ 99,193 The following is a maturity analysis of the annual undiscounted cash flows of the operating lease liabilities on a fiscal year basis, including common area maintenance fees, under non-cancelable operating leases as of June 30, 2022: Schedule of Future Minimum Annual Lease Commitments Under Operating Leases Fiscal Year Ending Minimum Lease September 30, Commitments 2022 (for the three months remaining) $ 29,532 2023 119,468 2024 123,543 2025 116,891 2026 - Total future undiscounted lease payments 389,434 Less interest 34,373 Present value of lease payments 355,061 Less current portion 100,685 Long-term operating lease liabilities $ 254,376 There Company does not have any obligations under finance leases as of June 30, 2022:

Notes Payable

Notes Payable	9 Months Ended
	Jun. 30, 2022
Debt Disclosure [Abstract]
Notes Payable	Note 7 – Notes Payable Notes payable consists of the following at June 30, 2022 and September 30, 2021, respectively: Schedule of Notes Payable June 30, 2022 September 30, 2021 On September 10, 2021, the Company, entered into a Secured Promissory note for $ 675,000 12 September 10, 2024 22,419.66 675,000 115,000 $ 790,000 $ 400,000 On December 26, 2019, the Company financed the purchase of $ 377,124 291,931 5.75 5,622 five-year term December 26, 2024 156,068 198,941 Total notes payable 946,068 598,941 Less: current maturities (545,880 ) (259,425 ) Notes payable $ 400,188 $ 339,516 The Company recorded interest expense pursuant to the stated interest rate and closing costs on the notes payable in the amount of $ 65,061 11,609

Convertible Notes Payable

Convertible Notes Payable	9 Months Ended
	Jun. 30, 2022
Debt Disclosure [Abstract]
Convertible Notes Payable	Note 8 – Convertible Notes Payable Convertible notes payable consists of the following at June 30, 2022 and September 30, 2021, respectively: Schedule of Convertible Notes Payable June 30, 2022 September 30, 2021 On February 11, 2020, the Company completed the sale to an accredited investor of a 9 50,000 August 11, 2022 9 0.15 0.03 10,000 60,000 10,000 333,334 0.03 $ 50,000 $ 50,000 On February 11, 2020, the Company completed the sale to an accredited investor of a 9 150,000 August 11, 2022 9 0.15 0.03 50,000 200,000 50,000 1,666,667 0.03 150,000 150,000 On February 10, 2020, the Company completed the sale to an accredited investor of a 9 350,000 August 10, 2022 9 0.15 0.03 50,000 400,000 50,000 1,666,667 0.03 350,000 350,000 On September 23, 2019, the Company received proceeds of $ 200,000 8 August 10, 2022 0.11 On September 30, 2020, the maturity date was extended to August 10, 2022 90,000 3,000,000 0.03 355,470 98,188 40,000 362,765 718,235 355,470 On November 8, 2018, the Company received proceeds of $ 350,000 8 August 10, 2022 0.14 0.03 350,000 350,000 On November 5, 2018, the Company received proceeds of $ 150,000 8 August 10, 2022 0.14 0.03 150,000 150,000 Total convertible notes payable 1,768,235 1,405,470 Less: unamortized debt discounts (39,533 ) (98,188 ) Total convertible debt 1,728,702 1,307,282 Less: current maturities 1,728,702 1,050,000 Convertible notes payable $ - $ 257,282 In addition, the Company recognized and measured the embedded beneficial conversion feature present in the convertible notes by allocating a portion of the proceeds equal to the intrinsic value of the feature to additional paid-in-capital. The intrinsic value of the feature was calculated on the commitment date using the effective conversion price of the convertible notes. This intrinsic value is limited to the portion of the proceeds allocated to the convertible debt. The aforementioned accounting treatment resulted in a total debt discount equal to $ 98,188 58,654 39,533 All of the convertible notes limit the maximum number of shares that can be owned by each note holder as a result of the conversions to common stock to 4.99 The Company recorded interest expense pursuant to the stated interest rates on the convertible notes in the amount of $ 79,795 61,099 The Company recognized interest expense for the nine months ended June 30, 2022 and 2021, respectively, as follows: Schedule of Interest Expense June 30, 2022 June 30, 2021 Interest on short term loans $ - $ 3,123 Interest on lease liabilities 13,106 6,477 Interest on notes payable 65,785 11,609 Amortization of beneficial conversion features 58,654 8,322 Interest on convertible notes 79,796 76,309 Total interest expense $ 217,341 $ 105,840

Changes in Stockholders_ Defici

Changes in Stockholders’ Deficit	9 Months Ended
	Jun. 30, 2022
Equity [Abstract]
Changes in Stockholders’ Deficit	Note 9 - Changes in Stockholders’ Deficit Convertible Preferred Stock The Company is authorized to issue 10,000,000 0.001 6,000,000 1,500,000 2,500,000 1,047,942 333,600 Series A The conversion price is adjustable in the event of stock splits and other adjustments in the Company’s capitalization, and in the event of certain negative actions undertaken by the Company. At the current conversion price, the 1,047,942 5,239,710 No holder is permitted to convert its shares of Series A Preferred if such conversion would cause the holder to beneficially own more than 4.99% of the issued and outstanding common stock of the Company immediately after such conversion, unless waived by such holder by providing at least sixty-five days’ notice. Additional terms of the Series A Preferred and include the following: ● The shares of Series A Preferred are entitled to dividends when, as and if declared by the Board as to the shares of the common stock of the Company into which such Series A Preferred may then be converted, subject to the 4.99 ● Upon the liquidation or dissolution of the Company, or any merger or sale of all or substantially all of the assets, the shares of Series A Preferred are entitled to receive, prior to any distribution to the holders of common stock, 100 ● The Series A Preferred plus all declared but unpaid dividends thereon automatically will be converted into common stock, at the then applicable conversion rate, upon the affirmative vote of the holders of a majority of the outstanding shares of Series A Preferred. ● Each share of Series A Preferred will carry a number of votes equal to the number of shares of common stock into which such Series A Preferred may then be converted, subject to the 4.99 ● Consent of the holders of the outstanding Series A Preferred is required in order for the Company to: (i) amend or change the rights, preferences, privileges or powers of, or the restrictions provided for the benefit of, the Series A Preferred; (ii) authorize, create or issue shares of any class of stock having rights, preferences, privileges or powers superior to the Series A Preferred; (iii) reclassify any outstanding shares into shares having rights, preferences, privileges or powers superior to the Series A Preferred; or (iv) amend the Company’s Articles of Incorporation or Bylaws in a manner that adversely affects the rights of the Series A Preferred. ● Pursuant to the Securities Purchase Agreements, holders of Series A Preferred are entitled to unlimited “piggyback” registration rights on registrations by the Company, subject to pro rata cutback at any underwriter’s discretion. During the nine months ended June 30, 2022, the Company offered to the Series A Preferred shareholders the ability to convert their Preferred A shares into Preferred B shares for an additional investment of 20% of their initial Series A investment. 55,600 55,600 278,000 Series B The Series B Preferred were designated on December 29, 2021. Each share of Series B Preferred has a Stated Value of $ 1.00 0.04 333,600 8,340,000 4.99 Additional terms of the Series B Preferred and include the following: ● The shares of Series B Preferred are not entitled to dividends, provided that if dividends are paid on the shares of common stock of the Company, the Series B Preferred will be entitled to dividends based on the number shares of common stock which the Series B Preferred may then be converted. ● Upon the liquidation or dissolution of the Company, or any merger or sale of all or substantially all of the assets, or upon a change in control whereby a stockholder gains control of 50% or more of the outstanding shares of common stock, the shares of Series B Preferred are entitled to receive, prior to any distribution to the holders of common stock, 100% of the purchase price per share of Series B Preferred plus all accrued but unpaid dividends. ● Each share of Series B Preferred carries a number of votes equal to the number of shares of common stock into which such Series B Preferred may then be converted. Due to the change in control provision of the Series B Preferred, the Series B Preferred is classified as temporary equity on the balance sheet. On December 30, 2021, the Company entered into an Exchange Agreement with one of the Company’s institutional investors (the “Investor”), pursuant to which the Investor exchanged 278,000 278,000 55,600 1.00 55,600 Common Stock Common stock consists of $ 0.001 250,000,000 75,146,820 During the nine months ended June 30, 2022, the Company issued 1,500,000 52,500 During the nine months ended June 30, 2022, the Company issued 2,166,667 91,000 During the nine months ended June 30, 2022, the Company issued 250,000 7,500

Common Stock Options

Common Stock Options	9 Months Ended
	Jun. 30, 2022
Share-Based Payment Arrangement [Abstract]
Common Stock Options	Note 10 – Common Stock Options Stock Incentive Plan On June 21, 2016, we amended and restated our 2012 Stock Incentive Plan (the “2012 Plan”), which was originally adopted on March 5, 2012 and previously amended on May 20, 2014. As amended, the 2012 Plan provides for the issuance of up to 11,500,000 6,020,000 During the nine months ended June 30, 2022, the Company issued to an unrelated third party, options to purchase 1,000,000 33,716 186 0.0337 0.035 Amortization of Stock-Based Compensation A total of $ 66,949 63,768 23,488 The following is a summary of information about the stock options outstanding at June 30, 2022. Summary of Common Stock Options Outstanding Shares Underlying Shares Underlying Options Outstanding Options Exercisable Weighted Shares Average Weighted Shares Weighted Range of Underlying Remaining Average Underlying Average Exercise Options Contractual Exercise Options Exercise Prices Outstanding Life Price Exercisable Price $ 0.05 0.13 6,020,000 6.26 $ 0.07 5,466,428 $ 0.07 The following is a summary of activity of outstanding common stock options: Schedule of Activity of Outstanding Common Stock Options Weighted Average Number Exercise of Shares Price Balance, September 30, 2021 5,620,000 $ 0.08 Options issued 1,000,000 $ 0.04 Options forfeited (600,000 ) $ 0.11 Balance, June 30, 2022 6,020,000 $ 0.07 Exercisable, June 30, 2022 5,466,428 $ 0.07 As of June 30, 2022, these options in the aggregate had no intrinsic value as the per share market price of $ 0.0125 0.07

Common Stock Warrants

Common Stock Warrants	9 Months Ended
	Jun. 30, 2022
Common Stock Warrants
Common Stock Warrants	Note 11 – Common Stock Warrants Warrants to purchase a total of 2,368,334 The following is a summary of information about our warrants to purchase common stock outstanding at June 30, 2022. Summary of Common Stock Warrants Outstanding Shares Underlying Shares Underlying Warrants Outstanding Warrants Exercisable Weighted Shares Average Weighted Shares Weighted Range of Underlying Remaining Average Underlying Average Exercise Warrants Contractual Exercise Warrants Exercise Prices Outstanding Life Price Exercisable Price $ 0.10 0.26 2,368,334 4.91 $ 0.16 2,368,334 $ 0.16 The following is a summary of activity of outstanding common stock warrants: Schedule of Outstanding Common Stock Warrants Activity Weighted Average Number Exercise of Shares Price Balance, September 30, 2021 2,535,001 $ 0.17 Warrants granted - - Warrants expired (166,667 ) 0.26 Balance, June 30, 2022 2,368,334 $ 0.16 Exercisable, June 30, 2022 2,368,334 $ 0.16 As of June 30, 2022, these warrants in the aggregate had no intrinsic value as the per share market price of $ 0.0125 0.16

Commitments and Contingencies

Commitments and Contingencies	9 Months Ended
	Jun. 30, 2022
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Note 12 – Commitments and Contingencies Legal Contingencies There are no material pending legal proceedings to which we are a party or to which any of our property is subject, nor are there any such proceedings known to be contemplated by governmental authorities. None of our directors, officers or affiliates is involved in a proceeding adverse to our business or has a material interest adverse to our business.

Subsequent Events

Subsequent Events	9 Months Ended
	Jun. 30, 2022
Subsequent Events [Abstract]
Subsequent Events	Note 13 – Subsequent Events On July 25, 2022, the Company entered into a Securities Purchase Agreement (the “Purchase Agreement”) with Todd Denkin, the Company’s President, pursuant to which Mr. Denkin purchased 1,000 0.10 The principal feature of the Series C Preferred Stock is that it provides the holder thereof, so long as he or she is an executive officer of the Company, with the ability to vote with the holders of the Company’s common stock on all matters presented to the holders of common stock, whether at a special or annual meeting, by written action in lieu of a meeting or otherwise, on the basis of 200,000 votes for each share of Series C Preferred Stock. The shares of Series C Preferred Stock are not convertible into common stock, are not entitled to dividends, are not subject to redemption, and have a stated value of $0.10 per share payable on any liquidation of the Company in preference to any payment payable to the holders of common stock.

Organization, Basis of Presen_2

Organization, Basis of Presentation and Significant Accounting Policies (Policies)	9 Months Ended
	Jun. 30, 2022
Accounting Policies [Abstract]
Organization	Organization Digipath, Inc. was incorporated in Nevada on October 5, 2010. Digipath, Inc. and its subsidiaries (“Digipath,” the “Company,” “we,” “our” or “us”) is a service-oriented independent testing laboratory, data analytics and media firm focused on the developing cannabis and hemp markets, and supports the cannabis industry’s best practices for reliable testing, cannabis education and training. Our mission is to provide pharmaceutical-grade analysis and testing to the cannabis industry, under ISO-17025:2017 guidelines, to ensure consumers and patients know exactly what is in the cannabis they ingest and to help maximize the quality of our clients’ products through research, development, and standardization. Digipath has been operating a cannabis-testing lab in Nevada since 2015 and hopes to open labs in other states that have legalized the sale of cannabis, beginning with California or Arizona.
Basis of Presentation	Basis of Presentation The accompanying consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“GAAP”). Intercompany accounts and transactions have been eliminated. The unaudited condensed consolidated financial statements of the Company and the accompanying notes included in this Quarterly Report on Form 10-Q are unaudited. In the opinion of management, all adjustments necessary for a fair presentation of the Condensed Consolidated Financial Statements have been included. Such adjustments are of a normal, recurring nature. The Condensed Consolidated Financial Statements, and the accompanying notes, are prepared in accordance with GAAP and do not contain certain information included in the Company’s Annual Report on Form 10-K for the fiscal year ended September 30, 2021. The interim Condensed Consolidated Financial Statements should be read in conjunction with that Annual Report on Form 10-K. Results for the interim periods presented are not necessarily indicative of the results that might be expected for the entire fiscal year.
Principles of Consolidation	Principles of Consolidation The accompanying consolidated financial statements include the accounts of the following entities, all of which were under common control and ownership at June 30, 2022: Schedule of Entities Under Common Control and Ownership Jurisdiction of Name of Entity (1) Incorporation Relationship Digipath, Inc. (2) Nevada Parent Digipath Labs, Inc. Nevada Subsidiary Digipath Labs CA, Inc. (3) California Subsidiary Digipath Labs S.A.S. (4) Colombia Subsidiary VSSL Enterprises, Ltd. (5) Canada Subsidiary TNM News Corp. (6) Nevada Subsidiary (1) All entities are in the form of a corporation. (2) Holding company, which owns each of the wholly-owned subsidiaries. All subsidiaries shown above are wholly-owned by Digipath, Inc., the parent company. (3) Formed during the second fiscal quarter of 2021, but has not yet commenced significant operations. (4) Formed during the first fiscal quarter of 2019, but has not yet commenced significant operations. (5) Acquired on March 11, 2020. (6) Minimal activity, dissolved on July 28, 2021. The consolidated financial statements herein contain the operations of the wholly-owned subsidiaries listed above. All significant inter-company transactions have been eliminated in the preparation of these financial statements. The parent company and subsidiaries will be collectively referred to herein as the “Company”, “Digipath” or “DIGP”. The Company’s headquarters are located in Las Vegas, Nevada and substantially all of its customers are within the United States. These statements reflect all adjustments, consisting of normal recurring adjustments, which in the opinion of management are necessary for fair presentation of the information contained therein.
Fair Value of Financial Instruments	Fair Value of Financial Instruments Under FASB ASC 820-10-05, the Financial Accounting Standards Board establishes a framework for measuring fair value in generally accepted accounting principles and expands disclosures about fair value measurements. This Statement reaffirms that fair value is the relevant measurement attribute. The adoption of this standard did not have a material effect on the Company’s financial statements as reflected herein. The carrying amounts of cash, accounts receivable, accounts payable and accrued expenses reported on the balance sheets are estimated by management to approximate fair value primarily due to the short-term nature of the instruments.
Revenue Recognition	Revenue Recognition The Company recognizes revenue in accordance with ASC 606 — Revenue from Contracts with Customers. Under ASC 606, the Company recognizes revenue from the commercial sales of products, licensing agreements and contracts to perform pilot studies by applying the following steps: (1) identify the contract with a customer; (2) identify the performance obligations in the contract; (3) determine the transaction price; (4) allocate the transaction price to each performance obligation in the contract; and (5) recognize revenue when each performance obligation is satisfied. Revenue is primarily generated through our subsidiary, Digipath Labs, Inc., which recognizes revenue from the analytical testing of cannabis products for licensed producers and cultivators within the state of Nevada on a determinable fixed fee per test, or panel of tests basis. Revenue from the performance of those services is recognized upon completion of the tests, at which time test results are delivered to the customer, provided collectability of the fee is reasonably assured. We typically require payment within thirty days of the delivery of results. Management estimates an allowance for doubtful accounts based on the aging of its receivables.
Stock-Based Compensation	Stock-Based Compensation The Company accounts for equity instruments issued to employees in accordance with the provisions of ASC 718 Stock Compensation (ASC 718) and Equity-Based Payments to Non-employees pursuant to ASC 2018-07 (ASC 2018-07). All transactions in which goods or services are the consideration received for the issuance of equity instruments are accounted for based on the fair value of the consideration received or the fair value of the equity instrument issued, whichever is more reliably measurable. The measurement date of the fair value of the equity instrument issued is the earlier of the date on which the counterparty’s performance is complete or the date at which a commitment for performance by the counterparty to earn the equity instruments is reached because of sufficiently large disincentives for nonperformance.
Recently Issued Accounting Pronouncements	Recently Issued Accounting Pronouncements There are no recently issued accounting pronouncements that the Company has yet to adopt that are expected to have a material effect on its financial position, results of operations, or cash flows.

Organization, Basis of Presen_3

Organization, Basis of Presentation and Significant Accounting Policies (Tables)	9 Months Ended
	Jun. 30, 2022
Accounting Policies [Abstract]
Schedule of Entities Under Common Control and Ownership	The accompanying consolidated financial statements include the accounts of the following entities, all of which were under common control and ownership at June 30, 2022: Schedule of Entities Under Common Control and Ownership Jurisdiction of Name of Entity (1) Incorporation Relationship Digipath, Inc. (2) Nevada Parent Digipath Labs, Inc. Nevada Subsidiary Digipath Labs CA, Inc. (3) California Subsidiary Digipath Labs S.A.S. (4) Colombia Subsidiary VSSL Enterprises, Ltd. (5) Canada Subsidiary TNM News Corp. (6) Nevada Subsidiary (1) All entities are in the form of a corporation. (2) Holding company, which owns each of the wholly-owned subsidiaries. All subsidiaries shown above are wholly-owned by Digipath, Inc., the parent company. (3) Formed during the second fiscal quarter of 2021, but has not yet commenced significant operations. (4) Formed during the first fiscal quarter of 2019, but has not yet commenced significant operations. (5) Acquired on March 11, 2020. (6) Minimal activity, dissolved on July 28, 2021.

Fair Value of Financial Instr_2

Fair Value of Financial Instruments (Tables)	9 Months Ended
	Jun. 30, 2022
Investments, All Other Investments [Abstract]
Summary of Financial Instruments at Fair Value on Recurring Basis	The following schedule summarizes the valuation of financial instruments at fair value on a recurring basis in the balance sheets as of June 30, 2022 and September 30, 2021, respectively: Summary of Financial Instruments at Fair Value on Recurring Basis Fair Value Measurements at June 30, 2022 Level 1 Level 2 Level 3 Assets Cash $ 225,233 $ - $ - Liabilities Lease liabilities - - 355,061 Notes payable - 946,068 - Convertible notes payable - - 1,728,701 Fair Value Measurements at September 30, 2021 Level 1 Level 2 Level 3 Assets Cash $ 295,932 $ - $ - Liabilities Lease liabilities - - 444,131 Notes payable - 598,941 - Convertible notes payable, net of discounts of $ 98,188 - - 1,307,282

Fixed Assets (Tables)

Fixed Assets (Tables)	9 Months Ended
	Jun. 30, 2022
Property, Plant and Equipment [Abstract]
Schedule of Fixed Assets	Fixed assets consist of the following at June 30, 2022 and September 30, 2021: Schedule of Fixed Assets June 30, 2022 September 30, 2021 Software $ 125,903 $ 125,903 Office equipment 71,601 71,601 Furniture and fixtures 29,879 29,879 Lab equipment 1,455,479 1,453,716 Leasehold improvements 496,600 494,117 Lab equipment held under capital leases 99,193 99,193 Fixed assets, gross 2,278,655 2,274,409 Less: accumulated depreciation (1,797,116 ) (1,627,157 ) Total $ 481,539 $ 647,252

Leases (Tables)

Leases (Tables)	9 Months Ended
	Jun. 30, 2022
Leases
Schedule of Components of Lease Expense	The components of lease expense were as follows: Schedule of Components of Lease Expense For the Nine For the Nine Months Ended Months Ended June 30, 2022 June 30, 2021 Operating lease cost $ 89,155 $ 6,477 Finance lease cost: Amortization of assets 72,187 68,408 Interest on lease liabilities 1,266 20,747 Total net lease cost $ 162,608 $ 95,632
Schedule of Supplemental Balance Sheet Information	Supplemental balance sheet information related to leases was as follows: Schedule of Supplemental Balance Sheet Information June 30, 2022 September 30, 2021 Operating leases: Operating lease assets $ 341,734 $ 413,884 Current portion of operating lease liabilities 100,685 $ 93,601 Noncurrent operating lease liabilities 254,376 330,151 Total operating lease liabilities $ 355,061 $ 423,752 Finance lease: Equipment, at cost $ 99,193 $ 99,193 Accumulated amortization (54,556 ) (39,677 ) Equipment, net $ 44,637 $ 59,516 Current portion of finance lease liabilities $ - $ 20,379 Noncurrent finance lease liabilities - - Total finance lease liabilities $ - $ 20,379 Weighted average remaining lease term: Operating leases 3.17 3.92 Finance leases 0.00 .55 Weighted average discount rate: Operating leases 5.75 % 5.75 % Finance lease 18.41 % 18.41 %
Schedule of Supplemental Cash Flow and Other Information	Supplemental cash flow and other information related to leases was as follows: Schedule of Supplemental Cash Flow and Other Information For the Nine For the Nine Months Ended Months Ended June 30, 2022 June 30, 2021 Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows used for operating leases $ 45,490 $ 62,471 Financing cash flows used for finance leases $ 20,379 $ 24,443 Leased assets obtained in exchange for lease liabilities: Total operating lease liabilities $ - $ 528,616 Total finance lease liabilities $ - $ 99,193
Schedule of Future Minimum Annual Lease Commitments Under Operating Leases	The following is a maturity analysis of the annual undiscounted cash flows of the operating lease liabilities on a fiscal year basis, including common area maintenance fees, under non-cancelable operating leases as of June 30, 2022: Schedule of Future Minimum Annual Lease Commitments Under Operating Leases Fiscal Year Ending Minimum Lease September 30, Commitments 2022 (for the three months remaining) $ 29,532 2023 119,468 2024 123,543 2025 116,891 2026 - Total future undiscounted lease payments 389,434 Less interest 34,373 Present value of lease payments 355,061 Less current portion 100,685 Long-term operating lease liabilities $ 254,376

Notes Payable (Tables)

Notes Payable (Tables)	9 Months Ended
	Jun. 30, 2022
Debt Disclosure [Abstract]
Schedule of Notes Payable	Notes payable consists of the following at June 30, 2022 and September 30, 2021, respectively: Schedule of Notes Payable June 30, 2022 September 30, 2021 On September 10, 2021, the Company, entered into a Secured Promissory note for $ 675,000 12 September 10, 2024 22,419.66 675,000 115,000 $ 790,000 $ 400,000 On December 26, 2019, the Company financed the purchase of $ 377,124 291,931 5.75 5,622 five-year term December 26, 2024 156,068 198,941 Total notes payable 946,068 598,941 Less: current maturities (545,880 ) (259,425 ) Notes payable $ 400,188 $ 339,516

Convertible Notes Payable (Tabl

Convertible Notes Payable (Tables)	9 Months Ended
	Jun. 30, 2022
Debt Disclosure [Abstract]
Schedule of Convertible Notes Payable	Convertible notes payable consists of the following at June 30, 2022 and September 30, 2021, respectively: Schedule of Convertible Notes Payable June 30, 2022 September 30, 2021 On February 11, 2020, the Company completed the sale to an accredited investor of a 9 50,000 August 11, 2022 9 0.15 0.03 10,000 60,000 10,000 333,334 0.03 $ 50,000 $ 50,000 On February 11, 2020, the Company completed the sale to an accredited investor of a 9 150,000 August 11, 2022 9 0.15 0.03 50,000 200,000 50,000 1,666,667 0.03 150,000 150,000 On February 10, 2020, the Company completed the sale to an accredited investor of a 9 350,000 August 10, 2022 9 0.15 0.03 50,000 400,000 50,000 1,666,667 0.03 350,000 350,000 On September 23, 2019, the Company received proceeds of $ 200,000 8 August 10, 2022 0.11 On September 30, 2020, the maturity date was extended to August 10, 2022 90,000 3,000,000 0.03 355,470 98,188 40,000 362,765 718,235 355,470 On November 8, 2018, the Company received proceeds of $ 350,000 8 August 10, 2022 0.14 0.03 350,000 350,000 On November 5, 2018, the Company received proceeds of $ 150,000 8 August 10, 2022 0.14 0.03 150,000 150,000 Total convertible notes payable 1,768,235 1,405,470 Less: unamortized debt discounts (39,533 ) (98,188 ) Total convertible debt 1,728,702 1,307,282 Less: current maturities 1,728,702 1,050,000 Convertible notes payable $ - $ 257,282
Schedule of Interest Expense	The Company recognized interest expense for the nine months ended June 30, 2022 and 2021, respectively, as follows: Schedule of Interest Expense June 30, 2022 June 30, 2021 Interest on short term loans $ - $ 3,123 Interest on lease liabilities 13,106 6,477 Interest on notes payable 65,785 11,609 Amortization of beneficial conversion features 58,654 8,322 Interest on convertible notes 79,796 76,309 Total interest expense $ 217,341 $ 105,840

Common Stock Options (Tables)

Common Stock Options (Tables)	9 Months Ended
	Jun. 30, 2022
Share-Based Payment Arrangement [Abstract]
Summary of Common Stock Options Outstanding	The following is a summary of information about the stock options outstanding at June 30, 2022. Summary of Common Stock Options Outstanding Shares Underlying Shares Underlying Options Outstanding Options Exercisable Weighted Shares Average Weighted Shares Weighted Range of Underlying Remaining Average Underlying Average Exercise Options Contractual Exercise Options Exercise Prices Outstanding Life Price Exercisable Price $ 0.05 0.13 6,020,000 6.26 $ 0.07 5,466,428 $ 0.07
Schedule of Activity of Outstanding Common Stock Options	The following is a summary of activity of outstanding common stock options: Schedule of Activity of Outstanding Common Stock Options Weighted Average Number Exercise of Shares Price Balance, September 30, 2021 5,620,000 $ 0.08 Options issued 1,000,000 $ 0.04 Options forfeited (600,000 ) $ 0.11 Balance, June 30, 2022 6,020,000 $ 0.07 Exercisable, June 30, 2022 5,466,428 $ 0.07

Common Stock Warrants (Tables)

Common Stock Warrants (Tables)	9 Months Ended
	Jun. 30, 2022
Common Stock Warrants
Summary of Common Stock Warrants Outstanding	The following is a summary of information about our warrants to purchase common stock outstanding at June 30, 2022. Summary of Common Stock Warrants Outstanding Shares Underlying Shares Underlying Warrants Outstanding Warrants Exercisable Weighted Shares Average Weighted Shares Weighted Range of Underlying Remaining Average Underlying Average Exercise Warrants Contractual Exercise Warrants Exercise Prices Outstanding Life Price Exercisable Price $ 0.10 0.26 2,368,334 4.91 $ 0.16 2,368,334 $ 0.16
Schedule of Outstanding Common Stock Warrants Activity	The following is a summary of activity of outstanding common stock warrants: Schedule of Outstanding Common Stock Warrants Activity Weighted Average Number Exercise of Shares Price Balance, September 30, 2021 2,535,001 $ 0.17 Warrants granted - - Warrants expired (166,667 ) 0.26 Balance, June 30, 2022 2,368,334 $ 0.16 Exercisable, June 30, 2022 2,368,334 $ 0.16

Schedule of Entities Under Comm

Schedule of Entities Under Common Control and Ownership (Details)	9 Months Ended
	Jun. 30, 2022
Entities Under Common Control and Ownership One [Member]
Name of Entity	Digipath, Inc.	[1],[2]
Jurisdiction of Incorporation	Nevada
Relationship	Parent
Entities Under Common Control and Ownership Two [Member]
Name of Entity	Digipath Labs, Inc.	[1]
Jurisdiction of Incorporation	Nevada
Relationship	Subsidiary
Entities Under Common Control and Ownership Three [Member]
Name of Entity	Digipath Labs CA, Inc.	[1],[3]
Jurisdiction of Incorporation	California
Relationship	Subsidiary
Entities Under Common Control and Ownership Four [Member]
Name of Entity	Digipath Labs S.A.S.	[1],[4]
Jurisdiction of Incorporation	Colombia
Relationship	Subsidiary
Entities Under Common Control and Ownership Five [Member]
Name of Entity	VSSL Enterprises, Ltd.	[1],[5]
Jurisdiction of Incorporation	Canada
Relationship	Subsidiary
Entities Under Common Control and Ownership Six [Member]
Name of Entity	TNM News Corp.	[1],[6]
Jurisdiction of Incorporation	Nevada
Relationship	Subsidiary
[1]All entities are in the form of a corporation.[2]Holding company, which owns each of the wholly-owned subsidiaries. All subsidiaries shown above are wholly-owned by Digipath, Inc., the parent company.[3]Formed during the second fiscal quarter of 2021, but has not yet commenced significant operations.[4]Formed during the first fiscal quarter of 2019, but has not yet commenced significant operations.[5]Acquired on March 11, 2020.[6]Minimal activity, dissolved on July 28, 2021.

Going Concern (Details Narrativ

Going Concern (Details Narrative) - USD ($)	Jun. 30, 2022	Sep. 30, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Working Capital	$ 2,189,146
Accumulated deficit	19,192,307	$ 17,951,653
Cash	$ 225,233	$ 295,932

Summary of Financial Instrument

Summary of Financial Instruments at Fair Value on Recurring Basis (Details) - USD ($)	Jun. 30, 2022	Sep. 30, 2021
Fair Value, Inputs, Level 1 [Member]
Defined Benefit Plan Disclosure [Line Items]
Cash	$ 225,233	$ 295,932
Lease liabilities
Note payable
Convertible notes payable, net of discounts
Fair Value, Inputs, Level 2 [Member]
Defined Benefit Plan Disclosure [Line Items]
Cash
Lease liabilities
Note payable	946,068	598,941
Convertible notes payable, net of discounts
Fair Value, Inputs, Level 3 [Member]
Defined Benefit Plan Disclosure [Line Items]
Cash
Lease liabilities	355,061	444,131
Note payable
Convertible notes payable, net of discounts	$ 1,728,701	$ 1,307,282

Summary of Financial Instrume_2

Summary of Financial Instruments at Fair Value on Recurring Basis (Details) (Parenthetical) - USD ($)	Jun. 30, 2022	Sep. 30, 2021
Short-Term Debt [Line Items]
Convertible notes discounts	$ 39,533	$ 98,188
Convertible Notes Payable [Member]
Short-Term Debt [Line Items]
Convertible notes discounts	$ 39,533	$ 98,188

Note Receivable (Details Narrat

Note Receivable (Details Narrative) - USD ($)	9 Months Ended	10 Months Ended
	Jun. 30, 2022	Jun. 30, 2022	Jun. 13, 2019
Defined Benefit Plan Disclosure [Line Items]
Interest income	$ 37,061
Accured interest	37,991	$ 37,991
Northwest Analytical Labs, Inc. [Member]
Defined Benefit Plan Disclosure [Line Items]
Notes receivable related parties			$ 95,000
Loans interest			10%
C3 Labs, Inc., [Member]
Defined Benefit Plan Disclosure [Line Items]
Notes receivable related parties	$ 1,047,649	$ 1,047,649
Loans interest	8%	8%
Debt Instrument, Maturity Date		Aug. 23, 2022
Allowance for receivable	$ 358,670	$ 358,670
Proceeds from sale of equipment	$ 175,000

Schedule of Fixed Assets (Detai

Schedule of Fixed Assets (Details) - USD ($)	Jun. 30, 2022	Sep. 30, 2021
Property, Plant and Equipment [Abstract]
Software	$ 125,903	$ 125,903
Office equipment	71,601	71,601
Furniture and fixtures	29,879	29,879
Lab equipment	1,455,479	1,453,716
Leasehold improvements	496,600	494,117
Lab equipment held under capital leases	99,193	99,193
Fixed assets, gross	2,278,655	2,274,409
Less: accumulated depreciation	(1,797,116)	(1,627,157)
Total	$ 481,539	$ 647,252

Fixed Assets (Details Narrative

Fixed Assets (Details Narrative) - USD ($)	9 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
Property, Plant and Equipment [Abstract]
Depreciation and amortization expense	$ 169,959	$ 233,663

Schedule of Components of Lease

Schedule of Components of Lease Expense (Details) - USD ($)	9 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
Leases
Operating lease cost	$ 89,155	$ 6,477
Amortization of assets	72,187	68,408
Interest on lease liabilities	1,266	20,747
Total net lease cost	$ 162,608	$ 95,632

Schedule of Supplemental Balanc

Schedule of Supplemental Balance Sheet Information (Details) - USD ($)	Jun. 30, 2022	Sep. 30, 2021
Leases
Operating lease assets	$ 341,734	$ 413,884
Current portion of operating lease liabilities	100,685	93,601
Noncurrent operating lease liabilities	254,376	330,151
Total operating lease liabilities	355,061	423,752
Equipment, at cost	99,193	99,193
Accumulated amortization	(54,556)	(39,677)
Equipment, net	44,637	59,516
Current portion of finance lease liabilities		20,379
Noncurrent finance lease liabilities
Total finance lease liabilities		$ 20,379
Weighted average remaining lease term operating leases	3 years 2 months 1 day	3 years 11 months 1 day
Weighted average remaining lease term Finance leases	0 years	6 months 18 days
Weighted average discount rate operating leases	5.75%	5.75%
Weighted average discount rate finance lease	18.41%	18.41%

Schedule of Supplemental Cash F

Schedule of Supplemental Cash Flow and Other Information (Details) - USD ($)	9 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
Leases
Operating cash flows used for operating leases	$ 45,490	$ 62,471
Financing cash flows used for finance leases	20,379	24,443
Total operating lease liabilities		528,616
Total finance lease liabilities		$ 99,193

Schedule of Future Minimum Annu

Schedule of Future Minimum Annual Lease Commitments Under Operating Leases (Details) - USD ($)	Jun. 30, 2022	Sep. 30, 2021
Leases
2022 (for the three months remaining)	$ 29,532
2023	119,468
2024	123,543
2025	116,891
2026
Total future undiscounted lease payments	389,434
Less interest	34,373
Present value of lease payments	355,061	$ 423,752
Less current portion	100,685	93,601
Long-term operating lease liabilities	$ 254,376	$ 330,151

Leases (Details Narrative)

Leases (Details Narrative)	9 Months Ended
	Jun. 30, 2022
Leases
Lease Expiration Date	Aug. 31, 2025

Schedule of Notes Payable (Deta

Schedule of Notes Payable (Details) - USD ($)	Jun. 30, 2022	Sep. 30, 2021
Short-Term Debt [Line Items]
Total notes payable	$ 946,068	$ 598,941
Less: current maturities	(545,880)	(259,425)
Notes payable	400,188	339,516
Notes Payable One [Member]
Short-Term Debt [Line Items]
Total notes payable	790,000	400,000
Notes Payable Two [Member]
Short-Term Debt [Line Items]
Total notes payable	$ 156,068	$ 198,941

Schedule of Notes Payable (De_2

Schedule of Notes Payable (Details) (Parenthetical) - USD ($)			9 Months Ended
	Sep. 10, 2021	Dec. 26, 2019	Jun. 30, 2022	Sep. 30, 2021
Short-Term Debt [Line Items]
Notes payable			$ 946,068	$ 598,941
Canna Lab Note [Member]
Short-Term Debt [Line Items]
Principal amount	$ 675,000
Debt instrument interest percentage	12%
Debt Instrument, Maturity Date	Sep. 10, 2024
Debt instrument periodic payment	$ 22,419.66
Notes payable			675,000
Secured Promissory Note [Member]
Short-Term Debt [Line Items]
Original debt amount			$ 115,000
Note Payable [Member]
Short-Term Debt [Line Items]
Debt instrument interest percentage		5.75%
Debt Instrument, Maturity Date		Dec. 26, 2024
Debt instrument periodic payment		$ 5,622
Payments for lab equipment		377,124
Proceeds from bank loan		$ 291,931
Debt instrument term description		five-year term

Schedule of Convertible Notes P

Schedule of Convertible Notes Payable (Details) - USD ($)	Jun. 30, 2022	Sep. 30, 2021
Short-Term Debt [Line Items]
Total convertible notes payable	$ 1,768,235	$ 1,405,470
Less: unamortized debt discounts	(39,533)	(98,188)
Total convertible debt	1,728,702	1,307,282
Less: current maturities	1,728,702	1,050,000
Convertible notes payable		257,282
Convertible Notes Payable One [Member]
Short-Term Debt [Line Items]
Total convertible notes payable	50,000	50,000
Convertible Notes Payable Two [Member]
Short-Term Debt [Line Items]
Total convertible notes payable	150,000	150,000
Convertible Notes Payable Three [Member]
Short-Term Debt [Line Items]
Total convertible notes payable	350,000	350,000
Convertible Notes Payable Four [Member]
Short-Term Debt [Line Items]
Total convertible notes payable	718,235	355,470
Convertible Notes Payable Five [Member]
Short-Term Debt [Line Items]
Total convertible notes payable	350,000	350,000
Convertible Notes Payable Six [Member]
Short-Term Debt [Line Items]
Total convertible notes payable	$ 150,000	$ 150,000

Schedule of Convertible Notes_2

Schedule of Convertible Notes Payable (Details) (Parenthetical) - USD ($)											9 Months Ended
	Sep. 30, 2021	Feb. 22, 2021	Dec. 29, 2020	Dec. 28, 2020	Sep. 30, 2020	Feb. 11, 2020	Feb. 10, 2020	Sep. 23, 2019	Nov. 08, 2018	Nov. 05, 2018	Jun. 30, 2022	Jun. 30, 2021
Short-Term Debt [Line Items]
Convertible debt											$ 402,765	$ 110,000
Amortization of debt discount premium											58,654	$ 8,322
Repayment of debt											40,000
Secured Convertible Promissory Note [Member] | Accredited Investors [Member]
Short-Term Debt [Line Items]
Debt instrument interest percentage						9%
Debt principal amount			$ 10,000	$ 60,000		$ 50,000
Debt Instrument, Maturity Date						Aug. 11, 2022
Conversion price per share			$ 0.03	$ 0.03		$ 0.15
Convertible debt				$ 10,000
Shares of common stock converted			333,334
Secured Subordinated Convertible Promissory Note [Member] | Accredited Investors [Member]
Short-Term Debt [Line Items]
Debt instrument interest percentage						9%
Debt principal amount			$ 50,000	$ 200,000		$ 150,000
Debt Instrument, Maturity Date						Aug. 11, 2022
Conversion price per share			$ 0.03	$ 0.03		$ 0.15
Convertible debt				$ 50,000
Shares of common stock converted			1,666,667
9% Secured Convertible Promissory Note [Member] | Accredited Investors [Member]
Short-Term Debt [Line Items]
Debt instrument interest percentage							9%
Debt principal amount			$ 50,000	$ 400,000			$ 350,000
Debt Instrument, Maturity Date							Aug. 10, 2022
Conversion price per share			$ 0.03	$ 0.03			$ 0.15
Convertible debt				$ 50,000
Shares of common stock converted			1,666,667
Senior Secured Convertible Note [Member]
Short-Term Debt [Line Items]
Debt instrument interest percentage								8%
Debt principal amount		$ 90,000						$ 200,000
Debt Instrument, Maturity Date					Aug. 10, 2022			Aug. 10, 2022
Conversion price per share		$ 0.03						$ 0.11
Convertible debt											362,765
Shares of common stock converted		3,000,000
Debt instrument maturity date description					On September 30, 2020, the maturity date was extended to August 10, 2022 and the conversion price was amended to $0.03 per share.
Debt instrument periodic payment	$ 355,470
Amortization of debt discount premium	$ 98,188
Repayment of debt											$ 40,000
Senior Secured Convertible Note One [Member]
Short-Term Debt [Line Items]
Debt instrument interest percentage									8%
Debt principal amount									$ 350,000
Debt Instrument, Maturity Date									Aug. 10, 2022
Conversion price per share					$ 0.03				$ 0.14
Senior Secured Convertible Note Two [Member]
Short-Term Debt [Line Items]
Debt instrument interest percentage										8%
Debt principal amount										$ 150,000
Debt Instrument, Maturity Date										Aug. 10, 2022
Conversion price per share					$ 0.03					$ 0.14

Notes Payable (Details Narrativ

Notes Payable (Details Narrative) - USD ($)	9 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
Note Payable [Member]
Short-Term Debt [Line Items]
Interest expense	$ 65,061	$ 11,609

Schedule of Interest Expense (D

Schedule of Interest Expense (Details) - USD ($)	3 Months Ended		9 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Debt Disclosure [Abstract]
Interest on short term loans				$ 3,123
Interest on lease liabilities			13,106	6,477
Interest on notes payable			65,785	11,609
Amortization of beneficial conversion features			58,654	8,322
Interest on convertible notes			79,796	76,309
Total interest expense	$ 72,230	$ 31,130	$ 217,341	$ 105,840

Convertible Notes Payable (Deta

Convertible Notes Payable (Details Narrative) - USD ($)	9 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Sep. 30, 2021
Short-Term Debt [Line Items]
Convertible notes discounts	$ 0		$ 8,322
Amortization of debt discounts	58,654	$ 8,322
Unamortized discounts	$ 39,533		98,188
Maximum Share Amount [Member]
Short-Term Debt [Line Items]
Maximum amount owned percentage of issued and outstanding common shares	4.99%
Convertible Notes Payable [Member]
Short-Term Debt [Line Items]
Convertible notes discounts	$ 98,188
Amortization of debt discounts	58,654
Unamortized discounts	39,533		$ 98,188
Convertible notes interest expense	$ 79,795	$ 61,099

Changes in Stockholders_ Defi_2

Changes in Stockholders’ Deficit (Details Narrative) - USD ($)		3 Months Ended						9 Months Ended
	Dec. 30, 2021	Jun. 30, 2022	Mar. 31, 2022	Dec. 31, 2021	Jun. 30, 2021	Mar. 31, 2021	Dec. 31, 2020	Jun. 30, 2022	Jun. 30, 2021	Sep. 30, 2021
Class of Stock [Line Items]
Preferred stock, shares authorized		6,000,000						6,000,000		6,000,000
Preferred stock, par value		$ 0.001						$ 0.001		$ 0.001
Preferred stock, shares issued		1,047,942						1,047,942		1,325,942
Preferred stock, shares outstanding		1,047,942						1,047,942		1,325,942
Purchase Price		100%						100%
Proceeds from issuance of preference stock								$ 55,600
Issuance of shares								250,000
Conversion of stock shares issued									8,340,000
Issued and outstanding common stock		4.99%						4.99%
Gross proceeds		$ 8,306	$ 103,464	$ 98,679	$ 79,500	$ 29,897	$ 44,060
Common stock par value		$ 0.001						$ 0.001		$ 0.001
Common stock authorized		250,000,000						250,000,000		250,000,000
Common stock, shares issued		75,146,820						75,146,820		71,230,153
Common stock, shares outstanding		75,146,820						75,146,820		71,230,153
Issuance of shares								$ 7,500
Common Stock [Member]
Class of Stock [Line Items]
Gross proceeds			$ 2,167	1,500	$ 1,465	$ 250	$ 1,228
Issuance of shares
Common Stock [Member] | Board Of Directors [Member]
Class of Stock [Line Items]
Issued for Services, Shares								1,500,000
Issued for Services, Value								$ 52,500
Common Stock [Member] | Third Party Consultants [Member]
Class of Stock [Line Items]
Issued for Services, Shares								2,166,667
Issued for Services, Value								$ 91,000
Series A Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock, shares authorized		10,000,000						10,000,000
Preferred stock, par value		$ 0.001						$ 0.001
Preferred stock, shares designated		6,000,000						6,000,000
Series B Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock, shares designated		1,500,000						1,500,000
Preferred stock, shares designated remaining		2,500,000						2,500,000
Series A Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock, shares issued		1,047,942						1,047,942
Preferred stock, shares outstanding		1,047,942						1,047,942
Conversion of stock shares converted								1,047,942
Number of shares converted		5,239,710						5,239,710
Common stock, conversion features								No holder is permitted to convert its shares of Series A Preferred if such conversion would cause the holder to beneficially own more than 4.99% of the issued and outstanding common stock of the Company immediately after such conversion, unless waived by such holder by providing at least sixty-five days’ notice.
Conversion of stock description								the Company offered to the Series A Preferred shareholders the ability to convert their Preferred A shares into Preferred B shares for an additional investment of 20% of their initial Series A investment.
Proceeds from issuance of preference stock								$ 55,600
Series A Preferred Stock [Member] | Exchange Agreement [Member]
Class of Stock [Line Items]
Conversion of stock shares converted	278,000
Series A Preferred Stock [Member] | Noteholders [Member]
Class of Stock [Line Items]
Percentage of equity beneficial ownership		4.99%						4.99%
Series B Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock, par value		$ 1						$ 1
Preferred stock, shares issued		333,600						333,600
Preferred stock, shares outstanding		333,600						333,600
Conversion of stock shares converted								333,600
Number of shares converted		278,000						278,000
Conversion of stock description								Upon the liquidation or dissolution of the Company, or any merger or sale of all or substantially all of the assets, or upon a change in control whereby a stockholder gains control of 50% or more of the outstanding shares of common stock, the shares of Series B Preferred are entitled to receive, prior to any distribution to the holders of common stock, 100% of the purchase price per share of Series B Preferred plus all accrued but unpaid dividends.
Issuance of shares								55,600
Conversion price		$ 0.04						$ 0.04
Shares, purchased	55,600
Share weighted average price of shares purchased	$ 1
Gross proceeds	$ 55,600
Series B Preferred Stock [Member] | Exchange Agreement [Member]
Class of Stock [Line Items]
Conversion of stock shares converted	278,000

Summary of Common Stock Options

Summary of Common Stock Options Outstanding (Details)	9 Months Ended
	Jun. 30, 2022 $ / shares shares
Share-Based Payment Arrangement [Abstract]
Range of Exercise Price, Minimum	$ 0.05
Range of Exercise Price, Maximum	$ 0.13
Number of Options Outstanding | shares	6,020,000
Weighted Average Remaining Contractual Life	6 years 3 months 3 days
Weighted Average Exercise Price	$ 0.07
Number of Shares Exercisable | shares	5,466,428
Weighted Average Exercise Price Exercisable	$ 0.07

Schedule of Activity of Outstan

Schedule of Activity of Outstanding Common Stock Options (Details)	9 Months Ended
	Jun. 30, 2022 $ / shares shares
Share-Based Payment Arrangement [Abstract]
Number of Shares Outstanding, Beginning balance | shares	5,620,000
Weighted Average Exercise Price, Beginning Balance | $ / shares	$ 0.08
Number of Shares Options Issued | shares	1,000,000
Weighted Average Exercise Price, Options Issued | $ / shares	$ 0.04
Number of Shares Options Forfeited | shares	(600,000)
Weighted Average Exercise Price, Options Forfeited | $ / shares	$ 0.11
Number of Shares Outstanding, Ending balance | shares	6,020,000
Weighted Average Exercise Price, Outstanding Ending | $ / shares	$ 0.07
Number of Shares Exercisable | shares	5,466,428
Weighted Average Exercise Price, Exercisable | $ / shares	$ 0.07

Common Stock Options (Details N

Common Stock Options (Details Narrative) - USD ($)		9 Months Ended
	Jun. 21, 2016	Jun. 30, 2022	Jun. 30, 2021	Sep. 30, 2021
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of options outstanding		6,020,000		5,620,000
Number of options granted to purchase shares of common stock		1,000,000
Weighted average exercise price, options issued		$ 0.04
Intrinsic value, market price per share		0.0125
Intrinsic value weighted-average exercise price per share		$ 0.07
Amortization of Stock Option [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Stock based compensation		$ 66,949	$ 63,768
Unamortized expenses expected to be expensed		23,488
Equity Option [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Stock issued during period, value, issued for services		$ 33,716
Stock option, volatility rate		186%
Call option values		$ 0.0337
Weighted average exercise price, options issued		$ 0.035
Equity Option [Member] | Common Stock [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of options granted to purchase shares of common stock		1,000,000
2012 Stock Incentive Plan [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of options outstanding		6,020,000
2012 Stock Incentive Plan [Member] | Maximum [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of shares issued under stock plan	11,500,000

Summary of Common Stock Warrant

Summary of Common Stock Warrants Outstanding (Details)	9 Months Ended
	Jun. 30, 2022 $ / shares shares
Common Stock Warrants
Range of Exercise Price, Minimum	$ 0.10
Range of Exercise Price, Maximum	$ 0.26
Number of Warrants Outstanding | shares	2,368,334
Weighted Average Remaining Contractual Life	4 years 10 months 28 days
Weighted Average Exercise Price	$ 0.16
Number of Warrants Exercisable | shares	2,368,334
Weighted Average Exercise Price, Exercisable	$ 0.16

Schedule of Outstanding Common

Schedule of Outstanding Common Stock Warrants Activity (Details)	9 Months Ended
	Jun. 30, 2022 $ / shares shares
Common Stock Warrants
Number of Shares, Balance beginning | shares	2,535,001
Weighted Average Exercise Price, Balance beginning | $ / shares	$ 0.17
Number of Shares, Warrants granted | shares
Weighted Average Exercise Price, Warrants granted | $ / shares
Number of Shares, Warrants expired | shares	(166,667)
Weighted Average Exercise Price, Warrants expired | $ / shares	$ 0.26
Number of Shares, Balance ending | shares	2,368,334
Weighted Average Exercise Price, Balance, ending | $ / shares	$ 0.16
Number of Shares, Exercisable | shares	2,368,334
Weighted Average Exercise Price, Exercisable | $ / shares	$ 0.16

Common Stock Warrants (Details

Common Stock Warrants (Details Narrative)	9 Months Ended
	Jun. 30, 2022 $ / shares shares
Number of warrant to purchase of common stock shares | shares	2,368,334
Intrinsic value, market price per share	$ 0.0125
Intrinsic value weighted-average exercise price per share	0.07
Warrant [Member]
Intrinsic value, market price per share	0.0125
Intrinsic value weighted-average exercise price per share	$ 0.16

Subsequent Events (Details Narr

Subsequent Events (Details Narrative) - $ / shares	Jul. 25, 2022	Jun. 30, 2022	Sep. 30, 2021
Subsequent Event [Line Items]
Preferred stock, shares designated		6,000,000	6,000,000
Subsequent Event [Member]
Subsequent Event [Line Items]
Common stock, voting rights	The principal feature of the Series C Preferred Stock is that it provides the holder thereof, so long as he or she is an executive officer of the Company, with the ability to vote with the holders of the Company’s common stock on all matters presented to the holders of common stock, whether at a special or annual meeting, by written action in lieu of a meeting or otherwise, on the basis of 200,000 votes for each share of Series C Preferred Stock. The shares of Series C Preferred Stock are not convertible into common stock, are not entitled to dividends, are not subject to redemption, and have a stated value of $0.10 per share payable on any liquidation of the Company in preference to any payment payable to the holders of common stock.
Series C Preferred Stock [Member] | Todd Denkin [Member] | Subsequent Event [Member]
Subsequent Event [Line Items]
Preferred stock, shares designated	1,000
Share price	$ 0.10